MRNX | Defiance Daily Target 2X Long MRNA ETF
$MRNX

MRNX

$

Defiance Daily Target 2X Long MRNA ETF

Name(Required)
Distribution Rate *
-%
Payable As of
Distribution Frequency
Monthly
30-Day SEC Yield **
As of —
-%
rating

Daily Target 2X Long MRNA (Moderna, Inc.) ETF

Overview

The Defiance Daily Target 2X Long MRNA ETF (MRNX) provides investors with amplified long exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company focused on the development and commercialization of messenger RNA (mRNA)–based medicines and vaccines. Moderna’s proprietary mRNA platform enables the rapid design and production of therapies across a range of disease areas, including infectious diseases and other unmet medical needs.

MRNX seeks to deliver 200% of the daily performance of MRNA’s stock, offering active traders a tactical way to express short-term bullish views on biotechnology innovation, mRNA-based drug development, vaccine demand dynamics, and advancements in next-generation therapeutic platforms—without the need for a margin account.

Investment Objective

The Fund seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Moderna, Inc. (NASDAQ: MRNA). The Fund does not seek to achieve its stated investment objective for a period other than a single trading day.

Underlying Stock: Moderna, Inc.

Moderna, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines based on messenger RNA technology. The company’s platform enables the design of mRNA-based therapeutics and vaccines across a range of disease areas, including infectious diseases and other unmet medical needs. Moderna, Inc. is listed on the Nasdaq Stock Market and is classified within the biotechnology industry.

An investment in the ETF is not a direct investment in Moderna, Inc.

The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. The Fund pursues daily leveraged investment objectives, which means it is riskier than alternatives that do not use leverage. The Fund magnifies the performance of the Underlying Security and is designed strictly for short-term use. For periods longer than a single day, the Fund’s performance will be the result of compounded daily returns, which is very likely to differ from 200% of the return of MRNA over the same period. It is possible that investors could lose their entire principal within a single trading day.

MRNXMarket Price

Performance

YTD 1 Month 3 Months 6 Months 1 Year 3 Years Since Inception
Total Return (NAV) (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% xx.xx%
1 Year Since Inception
Total Return (NAV) (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
Total Return (NAV) (%) xx.xx%
Market Price (%) xx.xx%
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 833.333.9383. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Market price is the price at which shares in the ETF can be brought or sold on the exchanges during trading hours, while the net asset value (NAV) represents the value of each share’s portion of the fund’s underlying assets and cash at the end of the trading day.

Fund Details

Data as of 02/17/2026
Net Assets $1.07M
Premium/discount -0.16%
NAV $21.30
Closing Price $21.27
Shares Outstanding 50,000
Median 30 Day Spread 0.53%
Fund inception 02/03/2026
Ticker MRNX
Primary Exchange NYSE
CUSIP 88636X815
Fund Holdings 7
NAV Symbol MRNX.NV
Expense Ratio 1.31%
30 Day SEC Yield* --%
* Yield as of 01-31-2026
Name Symbol Stock price % Net assets Shares Held Market Value
Moderna Inc Swap Cf-l 60770K107-TRS-09/08/28-L-MRNX $46.60 67.44% 17,279 $805,201
Moderna Inc Swap Nomura-l 60770K107-TRS-02/05/29-L-MRNX $46.60 48.79% 12,500 $582,500
Moderna Inc Swap Marex-l 60770K107-TRS-02/04/29-L-MRNX $46.60 43.71% 11,200 $521,920
Moderna Inc Swap Cs-l 60770K107-TRS-03/07/28-L-MRNX $46.60 40.02% 10,253 $477,790
United States Treasury Bill 03/19/2026 912797PV3 $99.72 10.02% 120,000 $119,662
First American Government Obligations Fund 12/01/2031 FGXXX $100.00 4.85% 57,950 $57,950
Cash & Other Cash&Other $1.00 -114.87% -1,371,619 $-1,371,619
Data as of 02/19/2026. Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
View full holdings
entries per page
Declaration Date
Ex-Div Date
Record Date
Payable Date
Amount ($)
12/29/2026
12/30/2026
12/30/2026
12/31/2026
$–
Declaration Date Ex-Div Date Record Date Payable Date Amount ($)
No records found
Distribution Rate *
Payable As of
-%
Distribution Frequency Monthly
30-Day SEC Yield **
As of —
-%